PDCs vs Antibody-Drug Conjugates Compared
Peptide-Drug Conjugates
<5 kDa vs 150 kDa
PDCs are roughly 30-fold smaller than antibody-drug conjugates, enabling deeper tumor penetration and faster renal clearance.
Wang et al., J Nanobiotechnology, 2025
Wang et al., J Nanobiotechnology, 2025
View as imageAntibody-drug conjugates (ADCs) are one of the fastest-growing drug classes in oncology, with 14 FDA-approved products and over 100 in clinical trials. They work by linking a cytotoxic drug to a monoclonal antibody that targets a tumor-specific antigen, delivering chemotherapy directly to cancer cells while sparing healthy tissue. But ADCs have structural limitations that no amount of engineering has fully solved: they are enormous molecules (~150 kDa) that struggle to penetrate deep into solid tumors, they are expensive to manufacture as biologics, and they can trigger immune responses. Peptide-drug conjugates (PDCs) take the same delivery concept but replace the antibody with a small tumor-targeting peptide, typically under 5 kDa.[1] This article compares the two platforms head to head. For broader context on PDC technology, see our pillar article on peptide-drug conjugates.
Key Takeaways
- PDCs are approximately 30-fold smaller than ADCs (~5 kDa vs ~150 kDa), enabling superior tissue penetration into solid tumor cores[1]
- PDCs are chemically synthesized, making them cheaper and more reproducible to manufacture than biologically produced ADCs[2]
- The small size of PDCs results in rapid renal clearance (minutes to hours), reducing systemic toxicity but requiring more frequent dosing[1]
- ADCs maintain longer circulation times (days to weeks) due to antibody-mediated FcRn recycling, giving them sustained tumor exposure
- Melflufen (Pepaxto) became the first FDA-approved PDC in 2021, though it was later withdrawn due to safety signals in a confirmatory trial[3]
The Core Architecture
Both ADCs and PDCs share the same three-component design: a targeting moiety, a linker, and a cytotoxic payload. The difference lies entirely in the targeting moiety.
ADCs use monoclonal antibodies (~150 kDa) that bind tumor-associated antigens with high affinity and specificity. The antibody provides a long circulating half-life (typically 2-4 weeks) through FcRn-mediated recycling, allowing sustained tumor exposure from a single infusion. The drug-to-antibody ratio (DAR) is typically 2-4 drug molecules per antibody.
PDCs use short peptides (typically 5-30 amino acids, <5 kDa) that target tumor-expressed receptors or exploit tumor microenvironment properties. Wang and colleagues identified three functional categories of peptides used in PDCs: tumor-targeting peptides that bind specific receptors, cell-penetrating peptides that facilitate intracellular delivery, and self-assembling peptides that form nanostructures at the tumor site.[1]
The size difference is roughly 30-fold. This single variable cascades into differences in tumor penetration, pharmacokinetics, manufacturing, immunogenicity, and clinical development timelines.
Tumor Penetration: The PDC Advantage
The most significant structural advantage of PDCs is tumor penetration. Solid tumors are not uniformly vascularized. The tumor periphery tends to have adequate blood supply, but the core is often hypoxic and poorly perfused, with dense extracellular matrix that acts as a physical barrier to large molecules.
Monoclonal antibodies (~150 kDa) diffuse slowly through tumor tissue. Studies have shown that ADCs tend to accumulate near tumor blood vessels, creating a "binding-site barrier" where the drug saturates receptors on the first cells it encounters and fails to reach deeper cell layers. This is a fundamental limitation for solid tumors, where the most resistant and aggressive cancer stem cells often reside in the poorly perfused core.
PDC molecules (~5 kDa) diffuse much more rapidly through tumor stroma. Their small size allows them to penetrate between cells and through extracellular matrix to reach tumor regions that ADCs cannot access.[2] He and colleagues demonstrated this principle by conjugating a PROTAC (targeted protein degrader) to the tumor-penetrating peptide iRGD, showing enhanced tumor targeting and deeper penetration compared to the unconjugated drug.[4]
This penetration advantage is most relevant for solid tumors, which account for approximately 90% of all cancers. For hematological malignancies (leukemias, lymphomas) where cancer cells circulate freely in blood, the penetration advantage is less meaningful, and ADCs' longer circulation time becomes the dominant factor. It is worth noting that many of the most successful ADCs to date (brentuximab vedotin for Hodgkin lymphoma, gemtuzumab ozogamicin for AML) target blood cancers where penetration is not a barrier, while the solid tumor ADC landscape has been more challenging to develop.
Pharmacokinetics: Speed vs Duration
The size difference creates opposite pharmacokinetic profiles:
ADCs: Half-life of days to weeks. The antibody component is recycled by FcRn receptors in endothelial cells, protecting it from degradation. This means a single infusion provides sustained drug delivery to tumors over weeks. The downside: prolonged circulation also means prolonged systemic exposure, contributing to off-target toxicity.
PDCs: Half-life of minutes to hours. Small peptides are rapidly cleared by renal filtration (kidneys filter molecules below ~60 kDa). This rapid clearance reduces systemic toxicity because the drug does not linger in circulation. The downside: faster clearance means less total drug exposure at the tumor site and the need for more frequent dosing.[1]
Researchers are working to extend PDC half-life without sacrificing the penetration advantage. Strategies include PEGylation (attaching polyethylene glycol chains), albumin binding (similar to the approach used in long-acting peptide hormones like semaglutide), and self-assembling nanostructures that create larger complexes at the tumor site while maintaining small injectable size. For a related discussion of how linker design affects drug release, see our article on PDC linker chemistry.
Manufacturing: Chemical vs Biological
This is where the "cheaper" part of the title comes in.
ADCs are biologics. The antibody component must be produced in mammalian cell culture (typically CHO cells), purified through multiple chromatography steps, conjugated to the drug payload, and subjected to extensive quality control. Each batch is slightly different because biological systems introduce variability. Manufacturing facilities require massive capital investment and GMP-compliant biological production infrastructure. The cost to manufacture an ADC is estimated at $100,000-$300,000 per kilogram of antibody, before conjugation.
PDCs are chemically synthesized, typically by solid-phase peptide synthesis (SPPS). This is the same technology used to manufacture other peptide drugs (somatostatin analogs, GnRH agonists, etc.). Chemical synthesis is reproducible batch-to-batch, scales more predictably, and requires less specialized infrastructure than biologics production.[2] The cost to synthesize a peptide is orders of magnitude lower than producing a monoclonal antibody.
Armstrong and colleagues noted that this manufacturing advantage translates to faster development timelines.[5] PDCs can move from discovery to clinical candidate more quickly because chemical synthesis allows rapid iteration on peptide sequence, linker chemistry, and payload selection without the biological production bottlenecks that slow ADC development.
Immunogenicity: Lower Risk With PDCs
Monoclonal antibodies are large, complex proteins that can trigger immune responses. Anti-drug antibodies (ADAs) can neutralize the therapeutic effect, alter pharmacokinetics, or cause allergic reactions. Humanized and fully human antibodies have reduced this problem, but it has not been eliminated. ADAs remain a concern in ADC clinical trials and can lead to treatment discontinuation.
Peptides are generally less immunogenic than antibodies because of their small size. Molecules below approximately 5 kDa are typically too small to elicit a robust adaptive immune response on their own.[1] This reduces the risk of neutralizing antibodies and allergic reactions, potentially allowing longer treatment courses. However, some peptide sequences can still trigger immune responses if they contain T-cell epitopes or are conjugated to immunogenic payloads. The immunogenicity advantage is probabilistic rather than absolute: PDCs are less likely to trigger immune responses than ADCs, but the risk is not zero. Repeated administration of any foreign peptide sequence carries some potential for immune recognition, particularly if the peptide is long enough to be presented on MHC molecules. Computational T-cell epitope screening can reduce this risk during PDC design.
Targeting Specificity: Where ADCs Still Lead
ADCs hold an advantage in targeting specificity and affinity. Monoclonal antibodies bind their target antigens with dissociation constants (Kd) in the low nanomolar to picomolar range, providing exquisite selectivity for tumor-expressed proteins.
Peptide targeting ligands typically have lower binding affinity (nanomolar to micromolar range) and may cross-react with related receptors. Rizvi and colleagues noted that while PDCs offer specificity and deeper tumor penetration, achieving the same target selectivity as antibodies remains a challenge for some peptide platforms.[2]
Several targeting strategies are being used in PDC development:
- RGD peptides: Target integrin receptors (overexpressed on tumor vasculature and many solid tumors). See our article on RGD-based PDCs.
- Somatostatin analogs: Target somatostatin receptors (overexpressed in neuroendocrine tumors). See our article on somatostatin PDCs.
- GnRH analogs: Target GnRH receptors (overexpressed in prostate, breast, and ovarian cancers).[6]
- Bombesin analogs: Target gastrin-releasing peptide receptors (overexpressed in prostate and breast cancers). For related research, see our article on bombesin peptides.
The Clinical Track Record
ADCs have a proven clinical track record: 14 FDA-approved products including trastuzumab deruxtecan (Enhertu) for HER2+ breast cancer, enfortumab vedotin (Padcev) for bladder cancer, and sacituzumab govitecan (Trodelvy) for triple-negative breast cancer. These drugs have demonstrated survival benefits in randomized trials.
PDCs have a shorter and more complicated clinical history. Melflufen (Pepaxto), a peptide-drug conjugate targeting aminopeptidase activity in myeloma cells, received accelerated FDA approval in 2021 for relapsed/refractory multiple myeloma.[3] However, it was voluntarily withdrawn from the market later that year after the confirmatory OCEAN trial showed a survival disadvantage compared to the control arm. This setback demonstrated that the PDC platform, while promising in concept, has not yet delivered a durable commercial success.
Multiple PDCs remain in clinical development, and recent reviews by Feng and colleagues (2026) and Sagar and colleagues (2025) describe an expanding pipeline.[7][8] Novel approaches including PROTAC-PDC hybrids (combining targeted protein degradation with peptide delivery) and self-assembling peptide nanostructures are in early-stage development.
Head-to-Head Comparison
Zana and colleagues published a direct comparison of small molecule-drug, antibody-drug, and peptide-drug conjugates, all targeting fibroblast activation protein (FAP), using the same cytotoxic payload.[9] This is one of the few studies that allows a true apples-to-apples comparison between the three delivery platforms with a shared target and payload. The study demonstrated that each platform has distinct pharmacokinetic and biodistribution profiles, and the optimal choice depends on the specific tumor type, target expression pattern, and desired exposure duration.
This finding underscores that PDCs and ADCs are not simply "better" or "worse" than each other. They are different tools suited to different clinical scenarios. PDCs may be optimal for solid tumors requiring deep penetration, patients at risk for anti-drug antibodies, or indications where rapid clearance and reduced systemic toxicity are priorities. ADCs may be optimal for targets with low expression (requiring high-affinity binding), hematological malignancies, or settings where sustained drug exposure is needed. For a broader view of tumor-targeting peptides beyond the PDC framework, see our article on the expanding library of tumor-targeting peptides.
What Remains Unresolved
No head-to-head randomized clinical trial has compared a PDC and an ADC targeting the same antigen in the same patient population. The comparative claims are based on preclinical data, pharmacokinetic modeling, and cross-trial comparisons. Until direct clinical comparisons exist, the relative clinical efficacy of the two platforms for any given indication remains theoretical.
The short half-life problem is not fully solved. While strategies like PEGylation and albumin binding can extend PDC circulation time, they may also increase molecular size and reduce the penetration advantage that motivates the PDC approach in the first place. Finding the optimal balance between circulation time and tissue penetration is an active area of research.
PDC target selection is more constrained than ADC target selection. ADCs can target any cell-surface antigen for which a high-affinity antibody can be raised, which is essentially any cell-surface protein. PDCs are limited to targets with known peptide ligands, which is a smaller set, though it is expanding through phage display, mRNA display, and AI-driven computational peptide design. As the library of validated tumor-targeting peptides grows, this constraint becomes less limiting. But for novel or rare tumor antigens, antibody-based approaches currently offer faster path-to-clinic because antibody discovery pipelines are more mature than peptide ligand discovery pipelines.
The melflufen withdrawal also raised questions about the PDC platform that remain unresolved. Was the survival disadvantage specific to melflufen's mechanism (aminopeptidase targeting rather than receptor-mediated delivery), or does it reflect a broader limitation of PDC pharmacokinetics? The short half-life of PDCs may lead to inconsistent drug delivery compared to the sustained exposure provided by ADCs, potentially allowing tumor cells time to repair between doses. These questions will only be answered as more PDCs advance through clinical trials with rigorous phase 3 designs.
The Bottom Line
Peptide-drug conjugates and antibody-drug conjugates represent fundamentally different approaches to the same goal: delivering cytotoxic drugs selectively to tumor cells. PDCs are approximately 30-fold smaller, offering superior solid tumor penetration, lower immunogenicity, and simpler chemical manufacturing. ADCs provide higher target affinity, longer circulation times, and a proven clinical track record with 14 FDA-approved products. The first FDA-approved PDC (melflufen) was withdrawn after a confirmatory trial failure, but the platform continues to advance with novel targeting strategies and hybrid designs. The two platforms are complementary rather than competitive, suited to different tumor types and clinical scenarios.